FULCRUM THERAPEUTICS, INC. (FULC)
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
📈 **POSITIVE** • Low confidence analysis (54%) • Moderate positive clinical data • Good growth prospects **Sentiment:** Positive (55%) **Content type:** Clinical